Q-omics provides the consensus-scored ARPC4-TTLL3 profile across patient tissues and cancer cell-line models. ARPC4-TTLL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ARPC4-TTLL3 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ARPC4-TTLL3 RNA expression shows 20,191 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, COAD, and THYM as cancer lineages where ARPC4-TTLL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPC4-TTLL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPC4-TTLL3 survival associations across molecular data types. ARPC4-TTLL3 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPC4-TTLL3 RNA expression–survival associations across cancer types. High ARPC4-TTLL3 expression shows unfavorable associations in KICH, ACC and LUSC, but favorable associations in SKCM, BLCA and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ARPC4-TTLL3 RNA expression.
This table summarizes ARPC4-TTLL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ARPC4-TTLL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPC4-TTLL3 shows lower tumor expression in BRCA and LUSC and higher tumor expression in COAD, KIRP, CHOL and LIHC. The COAD box plot shows higher ARPC4-TTLL3 RNA expression in tumor versus normal tissue (log2 FC = +0.364, t-test p < 0.001).
This table shows molecular features associated with ARPC4-TTLL3 in patient tissues and cancer cell lines. In patient samples, ARPC4-TTLL3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARPC4-TTLL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
